Edward Lee as new CEO of CUB Pharmaceutical Co., Ltd
Nov 12, 2025
|
Edward Lee, who has been an expert in market access, medical, health economy and performance research (HEOR) in the global pharmaceutical industry for more than 15 years, has extensive experience in patient-centered innovation and creating a sustainable health care ecosystem.
Since joining UCB in 2016, he has held key positions at its U.S. and British subsidiaries and Intercontinental headquarters. Until recently, he served as the General Manager of Patient Access, Sustainability, and External Engagement at Intercontinental Headquarters, and has led strategies to improve access to health care and strengthen health equity.
Prior to joining UCB, he worked at Astellas and Boehringer Ingelheim, where he led a number of new drug valuation and patient access improvement projects. He also holds a Ph.D. in Pharmacy from the University of Illinois, Chicago, USA, and has completed a Health Economy and Performance Study (HEOR) course through the joint fellowship program of Thomas Jefferson University and Daiichi Sankyo.
New CEO Edward Lee said, "Korea CUB Pharmaceutical will increase access to innovative treatments based on patient-centeredness and actively promote change and innovation to build a sustainable healthcare ecosystem."In the future, we will do our best to strengthen cooperation with patients, medical staff, the government, and various partners in the process of licensing new products and registering benefits so that domestic patients can receive treatment benefits more quickly." he said.
This article was translated by Naver AI translator.
